Dyne Therapeutics, Inc.
dyne-tx.comWhat Do They Do?
Develops targeted drug candidates for people with genetically driven neuromuscular diseases, including Duchenne muscular dystrophy, myotonic dystrophy and Pompe disease.
10-K for FY2025, filed Mar 2, 2026
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 2, 2026
Who Are Their Customers?
Its product candidates target people with genetically driven neuromuscular diseases; Dyne plans to commercialize approved products with an efficient, targeted sales force.
10-K for FY2025, filed Mar 2, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Jul 29, 2026
−$178.6MView ↗
- ▲ +61% (Loss)
- vs −$110.9M in Q2 FY2025
-
Jul 29, 2026
FDA accepts application for Dyne’s DMD treatment for priority review
The FDA set a January 21, 2027 target action date for z-rostudirsen.
Sources
8-K, filed Jul 29, 2026
- Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target…View ↗
More payload types
The platform’s payload range has expanded from oligonucleotides to include enzymes, with an enzyme replacement candidate for Pompe disease.
10-K for FY2022, filed Mar 2, 2023 10-K for FY2025, filed Mar 2, 2026
Delivery targets
The delivery goal has expanded from muscle tissue to include the central nervous system.
10-K for FY2022, filed Mar 2, 2023 10-K for FY2025, filed Mar 2, 2026
Who Do They Compete With?
Competes with PTC Therapeutics, Catalyst Pharmaceuticals, ITF Therapeutics, Sarepta Therapeutics, Nippon Shinyaku, Wave Life Sciences, Entrada Therapeutics, BioMarin Pharmaceuticals, SQY Therapeutics, NS Pharma, Avidity, Solid Biosciences, REGENXBIO, Insmed, Vertex, AMO Pharma, Harmony Biosciences, Pepgen, Arrowhead Pharmaceuticals, and Sanofi
10-K for FY2025, filed Mar 2, 2026Currently, patients with DMD are treated with corticosteroids to manage the inflammatory component of the disease. EMFLAZA (deflazacort) is…View ↗
Loading...
